SCHEMBL23214856

SCHEMBL23214856

CCN(CC)C(=O)Oc1ccc(C)c(Cl)c1C1CCNCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ TSHR P16473 1/20 0.43
▸ NPC1 O15118 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ HSD17B10 Q99714 2/20 0.36
▸ OPRD1 P41143 4/20 0.36
▸ OPRM1 P35372 3/20 0.36
▸ OPRK1 P41145 2/20 0.36
▸ SLC6A2 P23975 3/20 0.35
▸ SLC6A4 P31645 3/20 0.35
▸ SLC6A3 Q01959 2/20 0.35
▸ ACHE P22303 1/20 0.35
▸ MAOA P21397 1/20 0.34
▸ POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29885964 1.00 LMNA (0.44) LMNASMN1; SMN2TSHRNPC1MAPT
SCHEMBL23216381 0.88 LMNA (0.44) LMNASMN1; SMN2TSHRNPC1MAPT
SCHEMBL29886780 0.88 LMNA (0.44) LMNASMN1; SMN2TSHRNPC1MAPT
SCHEMBL29886227 0.87 LMNA (0.44) LMNASMN1; SMN2TSHRNPC1MAPT
SCHEMBL23216873 0.87 LMNA (0.44) LMNASMN1; SMN2TSHRNPC1MAPT
SCHEMBL23215172 0.79 ALDH1A1 (0.42) LMNASMN1; SMN2NPC1MAPTRAB9A
SCHEMBL29886059 0.79 ALDH1A1 (0.42) LMNASMN1; SMN2NPC1MAPTRAB9A
SCHEMBL23214982 0.72 QDPR (0.45) —
SCHEMBL29768394 0.72 QDPR (0.45) —
SCHEMBL23239810 0.70 LMNA (0.62) LMNASMN1; SMN2TSHRNPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230026611-A1 ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-01-26 — — US disclosed
US-20230026611-A1 ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-01-26 — — US disclosed
EP-4041407-A1 ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 — — EP disclosed
WO-2021071802-A1 ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 — — WO disclosed
WO-2021071802-A1 ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026611-A1 ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNA3, KCNH2, KCNJ2 LMNA 2534/4885SMN1; SMN2 2503/4885TSHR 1706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback